Global Drug-Device Combination Products Market by Product (Antimicrobial Catheters, Drug Eluting Stents, Infusion Pumps), Application (Antimicrobial Application, Cancer Treatment, Cardiovascular Disorder), End-user - Forecast 2024-2030

The Drug-Device Combination Products Market size was estimated at USD 133.95 billion in 2023, USD 144.59 billion in 2024, and is expected to grow at a CAGR of 8.09% to reach USD 231.05 billion by 2030.

A drug-device combination product is a unique class of healthcare products that combines pharmaceuticals and medical devices in a single unit. These products are designed to provide synergistic therapeutic benefits by integrating the pharmacological action of drugs with the physical performance of devices. The drug-device combination product offers innovative solutions for unmet medical needs or enhances existing therapies. Drug-device combination products deliver better patient outcomes compared to each component administered separately by combining drugs and devices into one product. This is primarily due to drug-targeted delivery at specific sites within the body, which increases efficacy while minimizing side effects or systemic toxicity. Incorporating advanced technologies, including smart sensors in these combination products, enables real-time monitoring and control over drug release profiles, which fosters personalized medicine approaches tailored to individual patient needs. Moreover, the prevalence of chronic diseases, including diabetes and heart ailments, has raised the need for minimally invasive and targeted treatment options. Ongoing efforts by regulatory authorities, including the U.S. FDA, to streamline approval processes for innovative combination products provide a favorable environment for manufacturers. However, complex regulatory frameworks and the high cost of research and development (R&D) activities significantly impede the adoption of drug-device combination products. In addition, manufacturers invest in research and development activities to address unmet clinical needs in areas such as targeted drug delivery systems or bioresorbable implants. Exploring new drug-device combinations to fight antibiotic-resistant infections or enhance cancer therapies is expected to create prospects for developing drug-device combination products.

Regional Insights

In the Americas, there is a growing need for drug-device combination products due to the increasing prevalence of chronic diseases, the aging population, technological advancements, and favorable reimbursement policies. The U.S. Food and Drug Administration (FDA) has been actively involved in approving patents and supporting research initiatives to develop drug-device combination products. In the Asia-Pacific, countries including China, Japan, India, and South Korea focus on cost-effective solutions to address unmet medical needs for their large patient pool suffering from chronic illnesses such as diabetes or cardiovascular diseases. China's National Medical Products Administration (NMPA) released new guidelines on clinical evaluation reports for medical devices promoting advancements in drug-device combination products. In addition, Japan's Pharmaceuticals and Medical Devices (PMD) Act ensures the quality, efficacy, and safety of pharmaceuticals, medical devices, and similar products. European Union countries have witnessed a surge in investment within biotechnology and medical device sectors, improving research activities on drug-device combination products. The European Medicines Agency (EMA) plays a vital role in evaluating these products' safety and efficacy. Major players collaborate with academic institutions to develop innovative solutions catering to specific regional demands. In the Middle East and Africa region, several regional governments focus on investing in healthcare infrastructure development that provides future growth opportunities for developing drug-device combination products.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Drug-Device Combination Products Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Drug-Device Combination Products Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Drug-Device Combination Products Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Braile Biomédica, Cardinal Health, Inc., CODAN Companies, Cook Group Incorporated, F. Hoffmann-La Roche AG, Fresenius Kabi, ICU Medical, Inc., InfuTronix, InSitu Technologies Inc., Insulet Corporation, JMS North America Corporation, Lepu Medical Technology Company, Medtronic PLC, MicroPort Scientific Corporation, Novartis AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., SOOIL Developments Co., Ltd., Stryker Corporation, Teleflex Incorporated, Terumo Corporation, Viatris Inc., W. L. Gore & Associates Inc., and Zyno Medical.

Market Segmentation & Coverage

This research report categorizes the Drug-Device Combination Products Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Antimicrobial Catheters
  • Drug Eluting Stents
  • Infusion Pumps
  • Inhalers
  • Orthopedic Combination Products
  • Photodynamic Therapy Devices
  • Prefilled Syringes
  • Transdermal Patches
  • Wound Care Products
• Application
  • Antimicrobial Application
  • Cancer Treatment
  • Cardiovascular Disorder
  • Diabetes
  • Respiratory Problem
• End-user
  • Ambulatory Surgery Centers
  • Home Care Settings
  • Hospital & Clinic

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

1. What is the market size and forecast of the Drug-Device Combination Products Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Drug-Device Combination Products Market?
3. What are the technology trends and regulatory frameworks in the Drug-Device Combination Products Market?
4. What is the market share of the leading vendors in the Drug-Device Combination Products Market?
5. Which modes and strategic moves are suitable for entering the Drug-Device Combination Products Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.